Sexually Transmitted Diseases (STD) Testing is used to detect all kinds of Sexually Transmitted virus.Sexually transmitted diseases are considered as one of the most critical health challenges globally. Chlamydia, gonorrhea, and herpes simplex virus are some of the highly prevalent sexually transmitted diseases.
麻豆原创 Analysis and Insights: Global Sexually Transmitted Diseases (STD) Testing 麻豆原创
The global Sexually Transmitted Diseases (STD) Testing market is projected to grow from US$ 83340 million in 2024 to US$ 100680 million by 2030, at a Compound Annual Growth Rate (CAGR) of 3.2% during the forecast period.
The US & Canada market for Sexually Transmitted Diseases (STD) Testing is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Sexually Transmitted Diseases (STD) Testing is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The Europe market for Sexually Transmitted Diseases (STD) Testing is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The global key companies of Sexually Transmitted Diseases (STD) Testing include ROCHE HOLDINGS, BIOMERIEUX, HOLOGIC, BECTON DICKINSON, ORASURE, DANAHER, AFFYMETRIX, ABBOTT LABORATORIES and BIO-RAD LABORATORIES, etc. In 2023, the global top five players had a share approximately % in terms of revenue.
Sexually Transmitted Diseases (STD) Testing is widely used in various fields, such as Laboratory Testing and Point of Care (POC) Testing, etc. Laboratory Testing provides greatest supports to the Sexually Transmitted Diseases (STD) Testing industry development. In 2023, global % revenue of Sexually Transmitted Diseases (STD) Testing went into Laboratory Testing filed and the proportion will reach to % in 2030.
Report Covers:
This report presents an overview of global market for Sexually Transmitted Diseases (STD) Testing market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Sexually Transmitted Diseases (STD) Testing, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Sexually Transmitted Diseases (STD) Testing, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Sexually Transmitted Diseases (STD) Testing revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Sexually Transmitted Diseases (STD) Testing market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Sexually Transmitted Diseases (STD) Testing revenue, projected growth trends, production technology, application and end-user industry.
麻豆原创 Segmentation
By Company
ROCHE HOLDINGS
BIOMERIEUX
HOLOGIC
BECTON DICKINSON
ORASURE
DANAHER
AFFYMETRIX
ABBOTT LABORATORIES
BIO-RAD LABORATORIES
DIASORIN
Segment by Type
Chlamydia
Syphilis
Gonorrhea
Herpes Simplex Virus
Human Papilloma Virus
Human Immunodeficiency Virus
Others
Segment by Application
Laboratory Testing
Point of Care (POC) Testing
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Sexually Transmitted Diseases (STD) Testing in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Sexually Transmitted Diseases (STD) Testing companies鈥� competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Sexually Transmitted Diseases (STD) Testing revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Chlamydia
1.2.3 Syphilis
1.2.4 Gonorrhea
1.2.5 Herpes Simplex Virus
1.2.6 Human Papilloma Virus
1.2.7 Human Immunodeficiency Virus
1.2.8 Others
1.3 麻豆原创 by Application
1.3.1 Global Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Laboratory Testing
1.3.3 Point of Care (POC) Testing
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Sexually Transmitted Diseases (STD) Testing 麻豆原创 Perspective (2019-2030)
2.2 Global Sexually Transmitted Diseases (STD) Testing Growth Trends by Region
2.2.1 Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Sexually Transmitted Diseases (STD) Testing Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Sexually Transmitted Diseases (STD) Testing Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Sexually Transmitted Diseases (STD) Testing 麻豆原创 Dynamics
2.3.1 Sexually Transmitted Diseases (STD) Testing Industry Trends
2.3.2 Sexually Transmitted Diseases (STD) Testing 麻豆原创 Drivers
2.3.3 Sexually Transmitted Diseases (STD) Testing 麻豆原创 Challenges
2.3.4 Sexually Transmitted Diseases (STD) Testing 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Sexually Transmitted Diseases (STD) Testing by Players
3.1.1 Global Sexually Transmitted Diseases (STD) Testing Revenue by Players (2019-2024)
3.1.2 Global Sexually Transmitted Diseases (STD) Testing Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Sexually Transmitted Diseases (STD) Testing 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Sexually Transmitted Diseases (STD) Testing, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Sexually Transmitted Diseases (STD) Testing 麻豆原创 Concentration Ratio
3.4.1 Global Sexually Transmitted Diseases (STD) Testing 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Sexually Transmitted Diseases (STD) Testing Revenue in 2023
3.5 Global Key Players of Sexually Transmitted Diseases (STD) Testing Head office and Area Served
3.6 Global Key Players of Sexually Transmitted Diseases (STD) Testing, Product and Application
3.7 Global Key Players of Sexually Transmitted Diseases (STD) Testing, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Sexually Transmitted Diseases (STD) Testing Breakdown Data by Type
4.1 Global Sexually Transmitted Diseases (STD) Testing Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Sexually Transmitted Diseases (STD) Testing Forecasted 麻豆原创 Size by Type (2025-2030)
5 Sexually Transmitted Diseases (STD) Testing Breakdown Data by Application
5.1 Global Sexually Transmitted Diseases (STD) Testing Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Sexually Transmitted Diseases (STD) Testing Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size (2019-2030)
6.2 North America Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size by Type
6.2.1 North America Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size by Type (2019-2024)
6.2.2 North America Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size by Type (2025-2030)
6.2.3 North America Sexually Transmitted Diseases (STD) Testing 麻豆原创 Share by Type (2019-2030)
6.3 North America Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size by Application
6.3.1 North America Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size by Application (2019-2024)
6.3.2 North America Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size by Application (2025-2030)
6.3.3 North America Sexually Transmitted Diseases (STD) Testing 麻豆原创 Share by Application (2019-2030)
6.4 North America Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size by Country
6.4.1 North America Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size by Country (2019-2024)
6.4.3 North America Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size by Country (2025-2030)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size (2019-2030)
7.2 Europe Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size by Type
7.2.1 Europe Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size by Type (2019-2024)
7.2.2 Europe Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size by Type (2025-2030)
7.2.3 Europe Sexually Transmitted Diseases (STD) Testing 麻豆原创 Share by Type (2019-2030)
7.3 Europe Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size by Application
7.3.1 Europe Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size by Application (2019-2024)
7.3.2 Europe Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size by Application (2025-2030)
7.3.3 Europe Sexually Transmitted Diseases (STD) Testing 麻豆原创 Share by Application (2019-2030)
7.4 Europe Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size by Country
7.4.1 Europe Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size by Country (2019-2024)
7.4.3 Europe Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size by Country (2025-2030)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size (2019-2030)
8.2 China Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size by Type
8.2.1 China Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size by Type (2019-2024)
8.2.2 China Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size by Type (2025-2030)
8.2.3 China Sexually Transmitted Diseases (STD) Testing 麻豆原创 Share by Type (2019-2030)
8.3 China Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size by Application
8.3.1 China Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size by Application (2019-2024)
8.3.2 China Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size by Application (2025-2030)
8.3.3 China Sexually Transmitted Diseases (STD) Testing 麻豆原创 Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size (2019-2030)
9.2 Asia Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size by Type
9.2.1 Asia Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size by Type (2019-2024)
9.2.2 Asia Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size by Type (2025-2030)
9.2.3 Asia Sexually Transmitted Diseases (STD) Testing 麻豆原创 Share by Type (2019-2030)
9.3 Asia Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size by Application
9.3.1 Asia Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size by Application (2019-2024)
9.3.2 Asia Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size by Application (2025-2030)
9.3.3 Asia Sexually Transmitted Diseases (STD) Testing 麻豆原创 Share by Application (2019-2030)
9.4 Asia Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size by Region
9.4.1 Asia Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size by Region (2019-2024)
9.4.3 Asia Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size (2019-2030)
10.2 Middle East, Africa, and Latin America Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size by Type
10.2.1 Middle East, Africa, and Latin America Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Sexually Transmitted Diseases (STD) Testing 麻豆原创 Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size by Application
10.3.1 Middle East, Africa, and Latin America Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Sexually Transmitted Diseases (STD) Testing 麻豆原创 Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size by Country
10.4.1 Middle East, Africa, and Latin America Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Sexually Transmitted Diseases (STD) Testing 麻豆原创 Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 ROCHE HOLDINGS
11.1.1 ROCHE HOLDINGS Company Details
11.1.2 ROCHE HOLDINGS Business Overview
11.1.3 ROCHE HOLDINGS Sexually Transmitted Diseases (STD) Testing Introduction
11.1.4 ROCHE HOLDINGS Revenue in Sexually Transmitted Diseases (STD) Testing Business (2019-2024)
11.1.5 ROCHE HOLDINGS Recent Developments
11.2 BIOMERIEUX
11.2.1 BIOMERIEUX Company Details
11.2.2 BIOMERIEUX Business Overview
11.2.3 BIOMERIEUX Sexually Transmitted Diseases (STD) Testing Introduction
11.2.4 BIOMERIEUX Revenue in Sexually Transmitted Diseases (STD) Testing Business (2019-2024)
11.2.5 BIOMERIEUX Recent Developments
11.3 HOLOGIC
11.3.1 HOLOGIC Company Details
11.3.2 HOLOGIC Business Overview
11.3.3 HOLOGIC Sexually Transmitted Diseases (STD) Testing Introduction
11.3.4 HOLOGIC Revenue in Sexually Transmitted Diseases (STD) Testing Business (2019-2024)
11.3.5 HOLOGIC Recent Developments
11.4 BECTON DICKINSON
11.4.1 BECTON DICKINSON Company Details
11.4.2 BECTON DICKINSON Business Overview
11.4.3 BECTON DICKINSON Sexually Transmitted Diseases (STD) Testing Introduction
11.4.4 BECTON DICKINSON Revenue in Sexually Transmitted Diseases (STD) Testing Business (2019-2024)
11.4.5 BECTON DICKINSON Recent Developments
11.5 ORASURE
11.5.1 ORASURE Company Details
11.5.2 ORASURE Business Overview
11.5.3 ORASURE Sexually Transmitted Diseases (STD) Testing Introduction
11.5.4 ORASURE Revenue in Sexually Transmitted Diseases (STD) Testing Business (2019-2024)
11.5.5 ORASURE Recent Developments
11.6 DANAHER
11.6.1 DANAHER Company Details
11.6.2 DANAHER Business Overview
11.6.3 DANAHER Sexually Transmitted Diseases (STD) Testing Introduction
11.6.4 DANAHER Revenue in Sexually Transmitted Diseases (STD) Testing Business (2019-2024)
11.6.5 DANAHER Recent Developments
11.7 AFFYMETRIX
11.7.1 AFFYMETRIX Company Details
11.7.2 AFFYMETRIX Business Overview
11.7.3 AFFYMETRIX Sexually Transmitted Diseases (STD) Testing Introduction
11.7.4 AFFYMETRIX Revenue in Sexually Transmitted Diseases (STD) Testing Business (2019-2024)
11.7.5 AFFYMETRIX Recent Developments
11.8 ABBOTT LABORATORIES
11.8.1 ABBOTT LABORATORIES Company Details
11.8.2 ABBOTT LABORATORIES Business Overview
11.8.3 ABBOTT LABORATORIES Sexually Transmitted Diseases (STD) Testing Introduction
11.8.4 ABBOTT LABORATORIES Revenue in Sexually Transmitted Diseases (STD) Testing Business (2019-2024)
11.8.5 ABBOTT LABORATORIES Recent Developments
11.9 BIO-RAD LABORATORIES
11.9.1 BIO-RAD LABORATORIES Company Details
11.9.2 BIO-RAD LABORATORIES Business Overview
11.9.3 BIO-RAD LABORATORIES Sexually Transmitted Diseases (STD) Testing Introduction
11.9.4 BIO-RAD LABORATORIES Revenue in Sexually Transmitted Diseases (STD) Testing Business (2019-2024)
11.9.5 BIO-RAD LABORATORIES Recent Developments
11.10 DIASORIN
11.10.1 DIASORIN Company Details
11.10.2 DIASORIN Business Overview
11.10.3 DIASORIN Sexually Transmitted Diseases (STD) Testing Introduction
11.10.4 DIASORIN Revenue in Sexually Transmitted Diseases (STD) Testing Business (2019-2024)
11.10.5 DIASORIN Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
ROCHE HOLDINGS
BIOMERIEUX
HOLOGIC
BECTON DICKINSON
ORASURE
DANAHER
AFFYMETRIX
ABBOTT LABORATORIES
BIO-RAD LABORATORIES
DIASORIN
听
听
*If Applicable.
